바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.76 No.4
Citation Share

Study Design and Outcomes of Korean Obstructive Lung Disease (KOLD) Cohort Study

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2014, v.76 no.4, pp.169-174









& (2014). Study Design and Outcomes of Korean Obstructive Lung Disease (KOLD) Cohort Study. Tuberculosis & Respiratory Diseases, 76(4), 169-174.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: The Korean Obstructive Lung Disease (KOLD) Cohort Study is a prospective longitudinal study of patients with chronic obstructive pulmonary disease (COPD), asthma, or other unclassified obstructive lung diseases. It was designed to develop new classification models and biomarkers that predict clinically relevant outcomes for patients with obstructive lung diseases. Methods: Patients over 18 years old who have chronic respiratory symptoms and airflow limitations or bronchial hyper-responsiveness were enrolled at 17 centers in South Korea. After a baseline visit, the subjects were followed up every 3 months for various assessments. Results: From June 2005 to October 2013, a total of 477 subjects (433 [91%] males; 381 [80%] diagnosed with COPD) were enrolled. Analyses of the KOLD Cohort Study identified distinct phenotypes in patients with COPD, and predictors of therapeutic responses and exacerbations as well as the factors related to pulmonary hypertension in COPD. In addition, several genotypes were associated with radiological phenotypes and therapeutic responses among Korean COPD patients. Conclusion: The KOLD Cohort Study is one of the leading long-term prospective longitudinal studies investigating heterogeneity of the COPD and is expected to provide new insights for pathogenesis and the long-term progression of COPD.

keywords
Biological Markers, Pulmonary Disease, Chronic Obstructive, Cohort Studies, Longitudinal Studies, Phenotype

Reference

1.

1. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412.

2.

2. Liu S, Zhou Y, Wang X, Wang D, Lu J, Zheng J, et al. Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007;62:889-97.

3.

3. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea:the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-65.

4.

4. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes:the future of COPD. Am J Respir Crit Care Med 2010;182:598-604.

5.

5. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.

6.

6. Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011;140:626-33.

7.

7. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:44-52.

8.

8. Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542-9.

9.

9. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. J Korean Med Sci 2011;26:379-85.

10.

10. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Different therapeutic responses in chronic obstructive pulmonary disease subgroups. Int J Tuberc Lung Dis 2011;15:1104-10.

11.

11. Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Response patterns to bronchodilator and quantitative computed tomography in chronic obstructive pulmonary disease. Clin Physiol Funct Imaging 2012;32:12-8.

12.

12. Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, et al. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008;186:381-6.

13.

13. Kim WJ, Sheen SS, Kim TH, Huh JW, Lee JH, Kim EK, et al. Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. Respirology 2009;14:260-3.

14.

14. Yoo JW, Hong Y, Seo JB, Chae EJ, Ra SW, Lee JH, et al. Comparison of clinico-physiologic and CT imaging risk factors for COPD exacerbation. J Korean Med Sci 2011;26:1606-12.

15.

15. Lee YK, Oh YM, Lee JH, Kim EK, Lee JH, Kim N, et al. Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography. Lung 2008;186:157-65.

16.

16. Chae EJ, Seo JB, Song JW, Kim N, Park BW, Lee YK, et al. Slope of emphysema index: an objective descriptor of regional heterogeneity of emphysema and an independent determinant of pulmonary function. AJR Am J Roentgenol 2010;194:W248-55.

17.

17. Kim WJ, Oh YM, Sung J, Lee YK, Seo JB, Kim N, et al. CT scanning-based phenotypes vary with ADRB2 polymorphisms in chronic obstructive pulmonary disease. Respir Med 2009;103:98-103.

18.

18. Jo KW, Ra SW, Chae EJ, Seo JB, Kim NK, Lee JH, et al. Three phenotypes of obstructive lung disease in the elderly. Int J Tuberc Lung Dis 2010;14:1481-8.

19.

19. Lee JH, Oh YM, Seo JB, Lee YK, Kim WJ, Sheen SS, et al. Pulmonary artery pressure in chronic obstructive pulmonary disease without resting hypoxaemia. Int J Tuberc Lung Dis 2011;15:830-7.

20.

20. Kim TB, Oh YM, Chang YS, Cho YS, Jang AS, Cho SH, et al. The reality of an intermediate type between asthma and COPD in practice. Respir Care 2012;57:1248-53.

21.

21. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema: an eight-year study of early chronic obstructive lung disease in working men in London. New York: Oxford University Press; 1976.

22.

22. Rennard SI, Vestbo J. Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:878-83.

23.

23. Foreman MG, Zhang L, Murphy J, Hansel NN, Make B, Hokanson JE, et al. Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med 2011;184:414-20.

24.

24. Kirkpatrick d P, Dransfield MT. Racial and sex differences in chronic obstructive pulmonary disease susceptibility, diagnosis, and treatment. Curr Opin Pulm Med 2009;15:100-4.

25.

25. Dransfield MT, Bailey WC. COPD: racial disparities in susceptibility, treatment, and outcomes. Clin Chest Med 2006;27:463-71.

26.

26. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009;374:733-43.

27.

27. Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M, et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals:SAPALDIA cohort study. Thorax 2006;61:671-7.

28.

28. de Marco R, Accordini S, Marcon A, Cerveri I, Anto JM, Gislason T, et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 2011;183:891-7.

29.

29. Han MK, Bartholmai B, Liu LX, Murray S, Curtis JL, Sciurba FC, et al. Clinical significance of radiologic characterizations in COPD. COPD 2009;6:459-67.

30.

30. ANOLD, Asian Network for Obstructive Lung Disease [Internet]. Seoul: ANOLD Coordination center; [cited 2013 Oct 11]. Available from: http://www.anold.org/.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy